Cellnovo Group S.A. | Income Statement

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
Sales/Revenue
-
124.70
608.50
1,419.00
1,062.00
Cost of Goods Sold (COGS) incl. D&A
521.70
1,999.40
6,542.80
7,066.00
8,197.00
Gross Income
521.70
1,874.60
5,934.20
5,647.00
7,135.00
SG&A Expense
5,576.90
5,004.20
9,237.90
8,968.00
11,103.00
EBIT
6,098.60
6,878.80
15,172.20
14,615.00
18,238.00
Unusual Expense
-
1,449.70
-
-
-
Non Operating Income/Expense
176.60
5.50
550.60
1.00
274.00
Interest Expense
30.90
1,643.00
1,059.10
571.00
681.00
Pretax Income
5,935.20
7,053.00
15,590.30
15,173.00
19,166.00
Income Tax
416.90
388.70
1,126.10
624.00
1,413.00
Consolidated Net Income
5,518.30
6,664.30
14,464.20
14,549.00
17,753.00
Net Income
5,518.30
6,664.30
14,464.20
14,549.00
17,753.00
Net Income After Extraordinaries
5,518.30
6,664.30
14,464.20
14,549.00
17,753.00
Net Income Available to Common
5,518.30
6,664.30
14,464.20
14,549.00
17,753.00
EPS (Basic)
0.52
0.62
2.45
1.34
1.24
Basic Shares Outstanding
10,683.90
10,683.90
5,895.50
10,874.80
14,367.10
EPS (Diluted)
0.52
0.62
2.45
1.34
1.24
Diluted Shares Outstanding
10,683.90
10,683.90
5,895.50
10,874.80
14,367.10
EBITDA
5,576.90
6,276.10
14,142.80
13,978.00
17,438.00
Non-Operating Interest Income
17.70
13.70
90.30
12.00
27.00

About Cellnovo Group

View Profile
Address
13, rue de Londres
Paris Ile-de-France 75009
France
Employees -
Website http://www.cellnovo.com
Updated 07/08/2019
Cellnovo Group SA is a medical technology company, which specializes in diabetes. The company develops and markets the first mobile, connected, all-in-one diabetes management system that helps make life easier for patients. Its products portfolio includes system, switch, pump therapy, and patient stories.